Arcus Biosciences (NYSE:RCUS) President Juan Jaen Sells 11,225 Shares

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 11,225 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $21.88, for a total transaction of $245,603.00. Following the completion of the sale, the president owned 355,995 shares of the company’s stock, valued at approximately $7,789,170.60. This represents a 3.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Arcus Biosciences Stock Down 1.2%

NYSE:RCUS opened at $22.02 on Friday. The company’s 50-day simple moving average is $20.96 and its 200-day simple moving average is $14.04. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65. Arcus Biosciences, Inc. has a fifty-two week low of $6.50 and a fifty-two week high of $26.40. The stock has a market capitalization of $2.38 billion, a P/E ratio of -6.40 and a beta of 0.75.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.33) by $0.06. The business had revenue of $26.00 million for the quarter, compared to analyst estimates of $19.89 million. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The business’s revenue for the quarter was down 45.8% on a year-over-year basis. During the same period in the previous year, the company earned ($1.00) earnings per share. On average, equities analysts anticipate that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

Institutional Trading of Arcus Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in RCUS. Vanguard Group Inc. lifted its holdings in Arcus Biosciences by 24.1% in the 1st quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company’s stock valued at $52,499,000 after purchasing an additional 1,298,584 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Arcus Biosciences by 23.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 714,002 shares of the company’s stock worth $5,605,000 after purchasing an additional 134,379 shares during the last quarter. Maryland State Retirement & Pension System grew its position in shares of Arcus Biosciences by 10.9% in the first quarter. Maryland State Retirement & Pension System now owns 20,202 shares of the company’s stock valued at $159,000 after purchasing an additional 1,986 shares in the last quarter. Swiss National Bank increased its holdings in shares of Arcus Biosciences by 35.9% in the first quarter. Swiss National Bank now owns 133,596 shares of the company’s stock valued at $1,049,000 after purchasing an additional 35,300 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in Arcus Biosciences by 24.5% during the first quarter. Invesco Ltd. now owns 254,024 shares of the company’s stock worth $1,994,000 after buying an additional 50,037 shares during the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

RCUS has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Wednesday, October 8th. UBS Group reiterated a “buy” rating on shares of Arcus Biosciences in a research note on Monday. Bank of America raised their target price on Arcus Biosciences from $17.00 to $26.00 and gave the stock a “neutral” rating in a research note on Friday, November 28th. Wells Fargo & Company increased their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Monday, October 20th. Finally, HC Wainwright lifted their target price on Arcus Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $28.89.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.